Page 97 - Read Online

Lv. J Transl Genet Genom 2021;5:414-22 https://dx.doi.org/10.20517/jtgg.2021.34 Page 422

61. Tsao CF, Huang WT, Liu TT, et al. Expression of high-mobility group box protein 1 in diabetic foot atherogenesis. Genet Mol Res
2015;14:4521-31. DOI PubMed
62. Qiu YW, Chen D, Xu MY, Li ST. Beneficial effects of dantrolene on sepsis-induced diaphragmatic dysfunction are associated with
downregulation of high-mobility group box 1 and calpain-caspase-3 proteolytic pathway. J Surg Res 2016;200:637-47. DOI PubMed
63. Xu K, Cai YS, Lu SM, et al. Autophagy induction contributes to the resistance to methotrexate treatment in rheumatoid arthritis
fibroblast-like synovial cells through high mobility group box chromosomal protein 1. Arthritis Res Ther 2015;17:374. DOI PubMed
PMC
64. Gnanasekar M, Kalyanasundaram R, Zheng G, et al. HMGB1: a promising therapeutic target for prostate cancer. Prostate Cancer
2013;2013:157103. DOI PubMed PMC
65. Wu X, Mi Y, Yang H, Hu A, Zhang Q, Shang C. The activation of HMGB1 as a progression factor on inflammation response in
normal human bronchial epithelial cells through RAGE/JNK/NF-κB pathway. Mol Cell Biochem 2013;380:249-57. DOI PubMed
66. He Q, You H, Li XM, Liu TH, Wang P, Wang BE. HMGB1 promotes the synthesis of pro-IL-1β and pro-IL-18 by activation of p38
MAPK and NF-κB through receptors for advanced glycation end-products in macrophages. Asian Pac J Cancer Prev 2012;13:1365-
70. DOI PubMed
67. Erikson JM, Valente AJ, Mummidi S, et al. Targeting TRAF3IP2 by genetic and interventional approaches inhibits
ischemia/reperfusion-induced myocardial injury and adverse remodeling. J Biol Chem 2017;292:2345-58. DOI PubMed PMC
68. van Hooren L, Sandin LC, Moskalev I, et al. Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-
PD1 prevents the growth of murine bladder cancer. Eur J Immunol 2017;47:385-93. DOI PubMed
69. Deng L, Stafford JH, Liu SC, et al. SDF-1 blockade enhances Anti-VEGF therapy of glioblastoma and can be monitored by MRI.
Neoplasia 2017;19:1-7. DOI PubMed PMC
70. Wang X, Xiang L, Li H, et al. The role of HMGB1 signaling pathway in the development and progression of hepatocellular carcinoma:
a review. Int J Mol Sci 2015;16:22527-40. DOI PubMed PMC
71. van Beijnum JR, Dings RP, van der Linden E, et al. Gene expression of tumor angiogenesis dissected: specific targeting of colon
cancer angiogenic vasculature. Blood 2006;108:2339-48. DOI PubMed
72. Kikuchi H, Yagi H, Hasegawa H, et al. Therapeutic potential of transgenic mesenchymal stem cells engineered to mediate anti-high
mobility group box 1 activity: targeting of colon cancer. J Surg Res 2014;190:134-43. DOI PubMed
73. Yang H, Pellegrini L, Napolitano A, et al. Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression.
Cell Death Dis 2015;6:e1786. DOI PubMed PMC
74. Smolarczyk R, Cichoń T, Matuszczak S, et al. The role of Glycyrrhizin, an inhibitor of HMGB1 protein, in anticancer therapy. Arch
Immunol Ther Exp (Warsz) 2012;60:391-9. DOI PubMed
75. Chang HY, Chen SY, Wu CH, Lu CC, Yen GC. Glycyrrhizin attenuates the process of epithelial-to-mesenchymal transition by
modulating HMGB1 initiated novel signaling pathway in prostate cancer cells. J Agric Food Chem 2019;67:3323-32. DOI PubMed
76. Li F, Chen Z, Pan Q, et al. The protective effect of PNU-282987, a selective α7 nicotinic acetylcholine receptor agonist, on the hepatic
ischemia-reperfusion injury is associated with the inhibition of high-mobility group box 1 protein expression and nuclear factor κB
activation in mice. Shock 2013;39:197-203. DOI PubMed
77. Nakamura Y, Nakano T, Irie K, et al. Recombinant human soluble thrombomodulin ameliorates cerebral ischemic injury through a
high-mobility group box 1 inhibitory mechanism without hemorrhagic complications in mice. J Neurol Sci 2016;362:278-82. DOI
PubMed
78. Li S, Eisenstadt R, Kumasaka K, et al. Does enoxaparin interfere with HMGB1 signaling after TBI? J Trauma Acute Care Surg
2016;80:381-7; discussion 387-9. DOI PubMed PMC
79. Hernandez C, Huebener P, Pradere JP, Antoine DJ, Friedman RA, Schwabe RF. HMGB1 links chronic liver injury to progenitor
responses and hepatocarcinogenesis. J Clin Invest 2018;128:2436-51. DOI PubMed PMC
80. Candolfi M, Yagiz K, Foulad D, et al. Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and
neurotoxicity. Clin Cancer Res 2009;15:4401-14. DOI PubMed PMC